Drugs Information:
Cenobamate
Basic Information
|
|
||
| ID | DDInter338 | |
| Drug Type | small molecule | |
| Molecular Formula | C10H10ClN5O2 | |
| Molecular Weight | 267.670 | |
| CAS Number | 913088-80-9 | |
| Description | Cenobamate, or YKP-3089, is an antiepileptic drug developed by SK Pharmaceuticals and used to treat partial onset seizures.[A188442,L10653] The exact mechanism of action has not been described in the literature, though it positively modulates GABAA and inhibits voltage gated sodium channels.[L10653] Cenobamate was granted FDA approval on 21 November 2019.[L10653] | |
| ATC Classification | N03AX25 | |
| IUPAC Name | (1R)-1-(2-chlorophenyl)-2-(2H-1,2,3,4-tetrazol-2-yl)ethyl carbamate | |
| InChI | GFHAXPJGXSQLPT-VIFPVBQESA-N | |
| Canonical SMILES | NC(=O)O[C@@H](CN1N=CN=N1)C1=C(Cl)C=CC=C1 | |
| Useful Links | DrugBank ChemSpider Wikipedia ChEMBL | |
Interactions with
Cenobamate
Filter:
| Severity level | ID | Name | Mechanism | Detail |
|---|
Interactions with diseases
Filter:
| Severity level | Disease name | Text | References |
|---|
Interactions with foods
Filter:
| Severity level | Food name | Description | Management | Mechanism | References |
|---|
Interactions with compound preparation
| Multi-DRUG trade | Multi-DRUG | Drug type | Warning | Note |
|---|